title: Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats.
abstract: BACKGROUND
  The development of analgesic tolerance following chronic morphine administration can be a significant clinical problem. Preclinical studies demonstrate that chronic morphine administration induces spinal gliosis and that inhibition of gliosis prevents the development of analgesic tolerance to opioids. Many studies have also demonstrated that ultra-low doses of naltrexone inhibit the development of spinal morphine antinociceptive tolerance and clinical studies demonstrate that it has opioid sparing effects. In this study we demonstrate that ultra-low dose naltrexone attenuates glial activation, which may contribute to its effects on attenuating tolerance.
  
  
  RESULTS
  Spinal cord sections from rats administered chronic morphine showed significantly increased immuno-labelling of astrocytes and microglia compared to saline controls, consistent with activation. 3-D images of astrocytes from animals administered chronic morphine had significantly larger volumes compared to saline controls. Co-injection of ultra-low dose naltrexone attenuated this increase in volume, but the mean volume differed from saline-treated and naltrexone-treated controls. Astrocyte and microglial immuno-labelling was attenuated in rats co-administered ultra-low dose naltrexone compared to morphine-treated rats and did not differ from controls. Glial activation, as characterized by immunohistochemical labelling and cell size, was positively correlated with the extent of tolerance developed. Morphine-induced glial activation was not due to cell proliferation as there was no difference observed in the total number of glial cells following chronic morphine treatment compared to controls. Furthermore, using 5-bromo-2-deoxyuridine, no increase in spinal cord cell proliferation was observed following chronic morphine administration.
  
  
  CONCLUSIONS
  Taken together, we demonstrate a positive correlation between the prevention of analgesic tolerance and the inhibition of spinal gliosis by treatment with ultra-low dose naltrexone. This research provides further validation for using ultra-low dose opioid receptor antagonists in the treatment of various pain syndromes.
authors.affiliation: Department of Pharmacology & Toxicology, Queen's University, Kingston, Ontario, K7L 3N6, Canada. 6tam1@queensu.ca
authors.forename: Theresa-Alexandra M
authors.initials: TA
authors.lastname: Mattioli
authors.forename: Brian
authors.initials: B
authors.lastname: Milne
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Cahill
mesh_terms: D000818:Animals; D004361:Drug Tolerance; D005911:Gliosis / Q000139:chemically induced* / Q000188:drug therapy*; D021621:Imaging, Three-Dimensional; D007150:Immunohistochemistry; D008297:Male; D009020:Morphine / Q000009:adverse effects* / Q000627:therapeutic use; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism
chemical_list: D009292:Narcotic Antagonists; D009271:Naltrexone; D009020:Morphine
references.citation: Eur J Pain. 1997;1(2):115-22
references.pmid: 15102412
references.citation: J Pain. 2005 Jun;6(6):392-9
references.pmid: 15943961
references.citation: J Neurosci. 1994 Apr;14(4):2301-12
references.pmid: 7908958
references.citation: Pain. 1988 Apr;33(1):11-23
references.pmid: 2454440
references.citation: Neuropharmacology. 1991 Nov;30(11):1233-9
references.pmid: 1663598
references.citation: Eur J Pharmacol. 2000 Oct 20;406(3):391-401
references.pmid: 11040346
references.citation: J Pharmacol Exp Ther. 1995 May;273(2):887-94
references.pmid: 7752094
references.citation: Clin Pharmacol Ther. 2008 Jan;83(1):144-52
references.pmid: 17568402
references.citation: Brain Res. 1995 Jul 24;686(2):239-48
references.pmid: 7583289
references.citation: Br J Pharmacol. 2000 Nov;131(5):875-84
references.pmid: 11053206
references.citation: Brain Res. 1999 May 22;829(1-2):209-21
references.pmid: 10350552
references.citation: Neuroscience. 2005;135(1):247-61
references.pmid: 16084657
references.citation: Pain Res Manag. 2009 Mar-Apr;14(2):103-8
references.pmid: 19532850
references.citation: Eur J Neurosci. 2004 Jan;19(2):479-84
references.pmid: 14725643
references.citation: Brain Res. 1997 May 23;757(2):176-90
references.pmid: 9200746
references.citation: Science. 1991 Jan 4;251(4989):85-7
references.pmid: 1824728
references.citation: Glia. 1998 Mar;22(3):249-59
references.pmid: 9482211
references.citation: Neuropsychopharmacology. 2004 Feb;29(2):327-34
references.pmid: 14532913
references.citation: Neurochem Res. 1990 Nov;15(11):1123-6
references.pmid: 1982460
references.citation: Neuroscience. 2009 Apr 10;159(4):1244-56
references.pmid: 19409222
references.citation: J Neurosci. 2003 May 15;23(10):4017-22
references.pmid: 12764087
references.citation: Trends Neurosci. 1996 Aug;19(8):312-8
references.pmid: 8843599
references.citation: Brain Res. 2006 Jan 19;1069(1):235-43
references.pmid: 16403466
references.citation: Pharmacol Biochem Behav. 1988 Mar;29(3):595-99
references.pmid: 3362954
references.citation: J Neurosci. 2002 Nov 15;22(22):9980-9
references.pmid: 12427855
references.citation: Pain Physician. 2008 Mar;11(2 Suppl):S105-20
references.pmid: 18443635
references.citation: ScientificWorldJournal. 2007 Nov 02;7:98-111
references.pmid: 17982582
references.citation: Brain Res. 1997 Dec 19;778(2):367-80
references.pmid: 9459554
references.citation: Proc Natl Acad Sci U S A. 1981 Jul;78(7):4185-9
references.pmid: 6117072
references.citation: Brain Behav Immun. 2007 Feb;21(2):131-46
references.pmid: 17175134
references.citation: J Pharmacol Exp Ther. 2005 Jun;313(3):1239-47
references.pmid: 15743926
references.citation: J Pain. 2006 Dec;7(12):937-46
references.pmid: 17157780
references.citation: Mol Pain. 2009 Sep 22;5:53
references.pmid: 19772627
references.citation: Pain. 2003 Aug;104(3):655-664
references.pmid: 12927638
references.citation: Mol Pain. 2007 Mar 12;3:7
references.pmid: 17352824
references.citation: Nature. 1996 Oct 31;383(6603):819-23
references.pmid: 8893006
references.citation: Brain Res Mol Brain Res. 1995 Dec 28;34(2):209-20
references.pmid: 8750824
references.citation: Neurosci Res. 2001 Mar;39(3):281-6
references.pmid: 11248367
references.citation: J Pharmacol Exp Ther. 2003 Aug;306(2):624-30
references.pmid: 12734393
references.citation: Trends Pharmacol Sci. 1990 Feb;11(2):77-81
references.pmid: 2156364
references.citation: J Pain. 2008 Aug;9(8):700-13
references.pmid: 18468954
references.citation: PLoS One. 2008 Feb 06;3(2):e1554
references.pmid: 18253501
references.citation: J Pharmacol Exp Ther. 2002 Feb;300(2):588-96
references.pmid: 11805221
references.citation: J Pharmacol Exp Ther. 2001 Jun;297(3):1210-7
references.pmid: 11356948
references.citation: Glia. 2004 Jan 1;45(1):89-95
references.pmid: 14648549
references.citation: Eur J Neurosci. 2003 Sep;18(6):1572-83
references.pmid: 14511336
references.citation: Brain Res. 1991 Nov 22;565(1):1-7
references.pmid: 1723019
references.citation: J Pain Symptom Manage. 2000 Jan;19(1 Suppl):S7-11
references.pmid: 10687332